We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Obesity Drugs Changing the Treatment Landscape
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Technology > Medical Devices > Obesity Drugs Changing the Treatment Landscape
BusinessMedical DevicesNews

Obesity Drugs Changing the Treatment Landscape

PatrickDriscoll
PatrickDriscoll
Share
1 Min Read
SHARE

 

 

The future of treatment in obesity is poised to shift as the FDA relents in its harsh stance against obesity drugs, now that the is reconsidering approval for Vivus’ Qnexa. A varied array of approaches and technologies are now used in the clinical management of obesity, spanning surgery with or without devices, devices without surgery and drugs. Restrictive devices (e.g., Lap-Band) and appetite suppressants currently represent the largest aggregate in the market, but with new drug approvals and the continued evolution of device-based obesity treatments, the balance of the market will change.

Below is illustrated the 2009 and forecast 2019 global market for obesity treatments categorized by type.  Device sales and new drugs will begin to gain a greater share of the market.

Source: MedMarket Diligence, LLC; Report #S835, “Products, Technologies and Markets Worldwide for the Clinical Management of Obesity, 2009-2019.”
      

TAGGED:obesityobesity drugs
Share This Article
Facebook Copy Link Print
Share
By PatrickDriscoll
Follow:
I serve the interests of medical technology company decision-makers, venture-capitalists, and others with interests in medtech producing worldwide analyses of medical technology markets for my audience of mostly medical technology companies (but also rapidly growing audience of biotech, VC, and other healthcare decision-makers). I have a small staff and go to my industry insiders (or find new ones as needed) to produce detailed, reality-grounded analyses of current and potential markets and opportunities. I am principally interested in those core clinical applications served by medical devices, which are expanding to include biomaterials, drug-device hybrids and other non-device technologies either competing head-on with devices or being integrated with devices in product development. The effort and pain of making every analysis global in scope is rewarded by my audience's loyalty, since in the vast majority of cases they too have global scope in their businesses.Specialties: Business analysis through syndicated reports, and select custom engagements, on medical technology applications and markets in general/abdominal/thoracic surgery, interventional cardiology, cardiothoracic surgery, patient monitoring/management, wound management, cell therapy, tissue engineering, gene therapy, nanotechnology, and others.

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026
Flat editorial illustration: The article connects routine occupational health screening with early exposure detection and better
What Routine Workplace Health Monitoring in Medical Environments Actually Prevents
Uncategorized
November 6, 2026
Flat editorial illustration: The article contrasts structured prelicensure education with ongoing, practice-focused development f
Academic vs. Clinical Education: How Teaching Settings Shape Nursing Learners and Outcomes
Uncategorized
November 6, 2026
Flat editorial illustration: Health-editorial illustration of the two-way relationship between substance use and disrupted sleep,
How Sleep Disruption Feeds the Addiction Cycle and What You Can Do About It
Addiction Recovery Mental Health Wellness
November 6, 2026

You Might also Like

Hoag Hospital Using daVinci Robot for Gynecologic Surgery Procedures

September 13, 2011
medical loss ratio
BusinessHealth ReformHospital AdministrationPolicy & Law

Medical Loss Ratio Reform: Barking Up the Wrong Tree

April 6, 2013
hearing loss
News

7 Painful Ways Untreated Hearing Loss Will Hurt Your Life

March 29, 2021
should nurse practitioner forms an LLC
BusinessCareerNursing

Should Nurse Practitioners Form an LLC?

December 14, 2022
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?